Concentration-QTcF analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemiaClin Transl Sci. 2024;17:e70065. Vaddady P, Smania G, Nakayama S, Inoue H, Kurumaddali A, Abutarif M, Zheng M.JournalOncologyPharmacometricsRegulatory interactionsPharmetheus Affiliates Principal Director, MIDD ConsultantGiovanni SmaniaSee bio Director, Quality Control & Medical Writing ConsultantChristina PentafragkaSee bioConnected publicationPopulation pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia